Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas
1994

Genetic Changes in Leiomyosarcomas

Sample size: 29 publication Evidence: moderate

Author Information

Author(s): H. Patterson, S. Gill, C. Fisher, M.G. Law, H. Jayatilake, C.D.M. Fletcher, M. Thomas, R. Grimer, B.A. Gusterson, C.S. Cooper

Primary Institution: Institute of Cancer Research

Hypothesis

Are abnormalities in the p53 and MDM2 genes important in the development of leiomyosarcomas?

Conclusion

Alterations in both the p53 gene and MDM2 gene are significant in a minority of leiomyosarcomas.

Supporting Evidence

  • 6 out of 29 tumors had point mutations in the p53 gene.
  • 5 of the 6 tumors with p53 mutations showed overexpression of the p53 protein.
  • 2 out of 29 tumors demonstrated amplification of the MDM2 gene.
  • Abnormalities in p53 or MDM2 genes were associated with more advanced tumor stages.

Takeaway

This study looked at tumors to see if certain genes were broken. They found that some tumors had problems with important genes that help stop cancer.

Methodology

The study used SSCP analysis, direct sequencing, and immunohistochemical staining to examine gene abnormalities.

Limitations

The study had a small sample size and focused only on specific genes.

Participant Demographics

29 patients, 20 males and 9 females, mean age 54 years.

Statistical Information

P-Value

0.03

Statistical Significance

p=0.03

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication